Journal
ORGANIC & BIOMOLECULAR CHEMISTRY
Volume 20, Issue 26, Pages 5342-5354Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2ob00764a
Keywords
-
Categories
Funding
- AIRC (Associazione Italiana per la Ricerca sul Cancro) [23267]
Ask authors/readers for more resources
A new biotin-based BNCT-MRI theranostic probe is reported, which combines the high tumor specificity of biotin and the selectivity of BNCT. The experimental results show that the probe has a high cellular uptake rate and MRI signal intensity increase in HeLa cells, indicating its potential therapeutic application.
A new biotin based BNCT (Boron Neutron Capture Therapy)-MRI theranostic is here reported (Gd-AL01) in order to exploit the high tumour specificity of biotin and the selectivity of BNCT in a synergistic manner. The key is the preparation of an intermediate where an o-carborane is linked to two amino groups orthogonally protected via the exploitation of two consecutive Mitsunobu reactions. The aim is its functionalisation in two different steps with biotin as the biological vector and Gd-DOTA as the MRI probe and GdNCT agent. Cell uptake was evaluated on HeLa tumour cells overexpressing biotin receptors. The internalised boron is proportional to the concentration of the theranostic agent incubated in the presence of cells. A maximum value of 77 ppm is reached and a well detectable signal intensity increase in the T-1 weighted image of HeLa cells was observed, differently from clinically used GdHPDO3A, where no contrast is detected. These excellent results indicate that Gd-AL01 can be applied as a theranostic probe in BNCT studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available